PeptidePedia The community reference

Contributions of MazdutideMads

User contributions·22 logged edits·page 1 of 1

Contributions by MazdutideMads, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,277 edits includes activity predating the current log.

  1. 18:00, 26 Jul 2026 (diff | hist) Asymchem Laboratories 17,160 ±0 m clarify that a registered business scope is a licensing fact, not a quality assurance
  2. 11:44, 6 Apr 2026 (diff | hist) Retatrutide 7,421 ±0 m move a stray full stop inside the reference
  3. 21:53, 17 Mar 2026 (diff | hist) Tirzepatide 8,037 ±0 add the molecular formula to the infobox
  4. 05:19, 19 Jan 2026 (diff | hist) International nonproprietary name 4,356 ±0 serial comma per PP:MOS
  5. 08:27, 14 Jan 2026 (diff | hist) Liraglutide 5,967 ±0 m convert a hard-coded date to the house format
  6. 20:50, 23 Dec 2025 (diff | hist) Orforglipron 5,647 ±0 add CAS number, sourced
  7. 22:30, 6 Dec 2025 (diff | hist) Karl Fischer titration 9,318 ±0 add the peptide-content point: area percent alone cannot give a mass
  8. 14:42, 17 Nov 2025 (diff | hist) Retatrutide 7,421 ±0 m the storage condition applies to the unopened pen; say so
  9. 03:03, 25 Oct 2025 (diff | hist) Fasting insulin 4,198 ±0 m correct the analyte name to the recommended nomenclature
  10. 05:07, 11 Sep 2025 (diff | hist) Lixisenatide 4,195 ±0 add the structural figure and caption it properly
  11. 20:40, 19 Jul 2025 (diff | hist) Dual incretin agonist 5,366 ±0 rm the equipotency claim — the cited paper does not make it
  12. 09:21, 16 May 2025 (diff | hist) International nonproprietary name 3,183 ±0 fix the amino-acid substitution — position 8, not position 2
  13. 11:25, 20 Dec 2024 (diff | hist) Amylin 3,694 +456 m add the receptor targets to the lead sentence
  14. 15:04, 18 Dec 2024 (diff | hist) Liraglutide 4,171 +898 fix hyphenation per PP:MOS
  15. 18:09, 6 Dec 2024 (diff | hist) Cagrilintide 2,970 +32 m give the strength per pen as well as per millilitre
  16. 07:20, 23 Sep 2024 (diff | hist) Triple agonist 1,171 +1,171 N start article on the compound
  17. 07:25, 21 Sep 2024 (diff | hist) Retatrutide 3,482 +132 expand §Design
  18. 18:30, 30 Aug 2024 (diff | hist) Medutest 2,537 ±0 rm a duplicated category
  19. 04:36, 30 Aug 2024 (diff | hist) Glucagon 3,441 +683 convert the substitution list to a table so the analogues line up
  20. 09:00, 22 Jul 2024 (diff | hist) Dual incretin agonist 2,297 +2,297 N new article: compound, expansion welcome
  21. 15:35, 12 Jul 2024 (diff | hist) Enteroendocrine L cell 1,903 ±0 m convert the receptor-distribution list to a table
  22. 17:03, 14 Jun 2024 (diff | hist) Semaglutide 2,577 ±0 m attribute the potency comparison to the head-to-head trial rather than to two separate ones